Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.

It will become really interesting how these highly significant preclinical effects translate in clinical efficacy in CKD patients as currently investigated in a clinical trial with runcaciguat in CKD patients. sGC activators and sGC stimulators in CKD Since early on potent and selective but also orally available sGC stimulators were available, there is also a quite substantial preclinical evidence for a kidney protective effect of sGC stimulators (for review, see Stasch et al., 2015 ).

also in 132,142 other papers